Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of TREDAPTIVE Tablet in Usual Practice.

Trial Profile

Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of TREDAPTIVE Tablet in Usual Practice.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2014

At a glance

  • Drugs Niacin/laropiprant (Primary)
  • Indications Dyslipidaemias; Hypercholesterolaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 01 May 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 27 Mar 2013 Planned end date changed from 1 Dec 2014 to 1 Aug 2013 as reported by ClinicalTrials.gov.
    • 27 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top